Grab A 5% Yield With GlaxoSmithKline plc, Standard Life Plc And Tate & Lyle PLC

These 3 stocks offer stunning income prospects: GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL) and Tate & Lyle PLC (LON: TATE).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With interest rates likely to remain low over the coming years, the ability to achieve a 5% yield on high quality companies is highly enticing. That’s especially the case when the prospects for a number of those stocks are upbeat and also because their future dividend growth could easily beat inflation.

Positive outlook

For example, Standard Life (LSE: SL) currently yields 5.4% and with the asset manager having a strong track record of increasing dividends per share, the outlook for future dividend growth is very positive. Shareholder payouts have risen by around 7.3% per annum during the last five years, which is considerably higher than the rate of inflation during that time. And with dividends being covered 1.4 times by profit, there’s clear scope for further rises moving forward.

In fact, Standard Life’s bottom line is expected to increase by 9% in 2017 and this should allow it to raise dividends by around 7.7%. This could act as a positive catalyst on the company’s share price and allow it to reverse the 35% fall over the last year. With Standard Life trading on a price-to-earnings growth (PEG) ratio of 1.3, it seems to offer excellent value for money, too.

Sweet pick

Also having a yield above 5% is Tate & Lyle (LSE: TATE). Although the last few years have been challenging for the business due to a variety of factors, including commodity pricing pressure and increased competition for the company’s products, it’s expected to turn things around in 2017 and 2018. In fact, its bottom line is forecast to rise by 10% in the next financial year, and by a further 5% in the year following that.

This turnaround could act as a positive catalyst not only on Tate & Lyle’s share price, but also on its dividend payments. With the company’s shareholder payouts being covered 1.3 times by profit, there’s scope to increase dividends at a similar pace to profit growth over the medium-to-long term. While further challenges could lie ahead, Tate & Lyle now seems to have a better organised supply chain through which to move forward, while its price-to-earnings (P/E) ratio of 15.3 indicates that there remains substantial upward rerating potential.

Non-cyclical star

Meanwhile, GlaxoSmithKline (LSE: GSK) continues to be one of the highest yielding shares in the FTSE 100. Its yield stands at 5.7% and while dividend growth is expected to be lacking over the next couple of years, GlaxoSmithKline has the potential to raise dividends at a rapid rate over the long term.

A key reason for that is the changes the company is making to its business model. It’s seeking to drive through over £1bn in cost savings in the next few years and this could help to improve profitability. Furthermore, GlaxoSmithKline’s dividend growth should be positively impacted by its impressive and diversified pipeline of new drugs that have the potential to reinvigorate its bottom line following a period of rather lacklustre growth.

As well as a top-notch yield and upbeat dividend growth prospects, GlaxoSmithKline remains a relatively defensive option. It has a beta of 0.9, which indicates that its shares should be less volatile than the wider index, while its lack of cyclicality means that its shares could rise even if the macroeconomic outlook remains uncertain.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline, Standard Life, and Tate & Lyle. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Is the S&P 500 going to 10,000 by 2030? This expert thinks so

One stock market strategist sees animal spirits taking hold and driving the S&P 500 index even higher by the end…

Read more »